NZ724435B2 - Multipotent stem cells from the extrahepatic biliary tree and methods of isolating same - Google Patents
Multipotent stem cells from the extrahepatic biliary tree and methods of isolating same Download PDFInfo
- Publication number
- NZ724435B2 NZ724435B2 NZ724435A NZ72443510A NZ724435B2 NZ 724435 B2 NZ724435 B2 NZ 724435B2 NZ 724435 A NZ724435 A NZ 724435A NZ 72443510 A NZ72443510 A NZ 72443510A NZ 724435 B2 NZ724435 B2 NZ 724435B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- expression
- cell
- biliary tree
- stem
- Prior art date
Links
- 210000003445 Biliary Tract Anatomy 0.000 title claims abstract description 141
- 210000004253 Multipotent Stem Cells Anatomy 0.000 title claims abstract description 25
- 210000004027 cells Anatomy 0.000 claims abstract description 247
- 210000000130 stem cell Anatomy 0.000 claims abstract description 174
- 230000014509 gene expression Effects 0.000 claims abstract description 69
- 210000001519 tissues Anatomy 0.000 claims abstract description 62
- 210000004185 Liver Anatomy 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 210000003494 Hepatocytes Anatomy 0.000 claims abstract description 28
- 210000004153 Islets of Langerhans Anatomy 0.000 claims abstract description 24
- 210000000013 Bile Ducts Anatomy 0.000 claims abstract description 17
- 102000003995 transcription factors Human genes 0.000 claims abstract description 17
- 108090000464 transcription factors Proteins 0.000 claims abstract description 17
- 210000002889 Endothelial Cells Anatomy 0.000 claims abstract description 10
- 102000004591 Telomerase Human genes 0.000 claims abstract description 9
- 108010017842 Telomerase Proteins 0.000 claims abstract description 9
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 210000004524 haematopoietic cell Anatomy 0.000 claims abstract description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 40
- 210000000496 Pancreas Anatomy 0.000 claims description 31
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 28
- 102000004877 Insulin Human genes 0.000 claims description 20
- 108090001061 Insulin Proteins 0.000 claims description 20
- 239000003550 marker Substances 0.000 claims description 18
- 101700057304 SOX17 Proteins 0.000 claims description 15
- 102000005908 AC133 Antigen Human genes 0.000 claims description 14
- 108010005465 AC133 Antigen Proteins 0.000 claims description 14
- 108060003199 Glucagon Proteins 0.000 claims description 12
- 229960004666 Glucagon Drugs 0.000 claims description 12
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 12
- 101700030874 SOX9 Proteins 0.000 claims description 11
- -1 HES l Proteins 0.000 claims description 10
- 102100006141 FOXA2 Human genes 0.000 claims description 7
- 102100005389 SOX17 Human genes 0.000 claims description 7
- 101710010695 ONECUT1 Proteins 0.000 claims description 6
- 102100019962 ONECUT1 Human genes 0.000 claims description 6
- 102100003588 SCTR Human genes 0.000 claims description 6
- 101700074725 SCTR Proteins 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 210000002894 multi-fate stem cell Anatomy 0.000 claims description 6
- 101700049079 FOXA2 Proteins 0.000 claims description 5
- 101700077314 PDX1 Proteins 0.000 claims description 5
- 101710034857 ATIC Proteins 0.000 claims description 4
- 239000004382 Amylase Substances 0.000 claims description 3
- 102000013142 Amylases Human genes 0.000 claims description 3
- 108010065511 Amylases Proteins 0.000 claims description 3
- 102100011908 NRCAM Human genes 0.000 claims description 3
- 101700048788 NRCAM Proteins 0.000 claims description 3
- 102000005157 Somatostatin Human genes 0.000 claims description 3
- 108010056088 Somatostatin Proteins 0.000 claims description 3
- 229960000553 Somatostatin Drugs 0.000 claims description 3
- 108091007928 VEGF receptors Proteins 0.000 claims description 3
- 235000019418 amylase Nutrition 0.000 claims description 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
- 102000010637 Aquaporins Human genes 0.000 claims description 2
- 108010063290 Aquaporins Proteins 0.000 claims description 2
- 102100000789 DES Human genes 0.000 claims description 2
- 108010044052 Desmin Proteins 0.000 claims description 2
- 102100007544 NCAM1 Human genes 0.000 claims description 2
- 101700077124 NCAM1 Proteins 0.000 claims description 2
- 101710022625 NEUROG3 Proteins 0.000 claims description 2
- 102100018315 NEUROG3 Human genes 0.000 claims description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 2
- 210000004962 mammalian cells Anatomy 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 102100002212 CXCR4 Human genes 0.000 claims 1
- 101710003734 CXCR4 Proteins 0.000 claims 1
- 102100005499 PTPRC Human genes 0.000 claims 1
- 101700059076 PTPRC Proteins 0.000 claims 1
- 239000002609 media Substances 0.000 description 60
- 230000001058 adult Effects 0.000 description 31
- 230000004069 differentiation Effects 0.000 description 30
- 102100010912 EPCAM Human genes 0.000 description 26
- 229920002674 hyaluronan Polymers 0.000 description 26
- 102100001249 ALB Human genes 0.000 description 24
- 210000004907 Glands Anatomy 0.000 description 23
- 101710027066 ALB Proteins 0.000 description 21
- 229940050528 albumin Drugs 0.000 description 21
- 229920003023 plastic Polymers 0.000 description 19
- 210000000232 Gallbladder Anatomy 0.000 description 16
- 239000006285 cell suspension Substances 0.000 description 15
- 239000011159 matrix material Substances 0.000 description 15
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 14
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 14
- 210000001096 Cystic Duct Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000017 hydrogel Substances 0.000 description 13
- 239000007640 basal medium Substances 0.000 description 12
- 238000003757 reverse transcription PCR Methods 0.000 description 12
- 210000004940 Nucleus Anatomy 0.000 description 11
- 102000004338 Transferrin Human genes 0.000 description 11
- 108090000901 Transferrin Proteins 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 11
- 239000012581 transferrin Substances 0.000 description 11
- 102100000690 CHL1 Human genes 0.000 description 10
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 10
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 10
- 108010085895 Laminin Proteins 0.000 description 10
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 10
- 229910052802 copper Inorganic materials 0.000 description 10
- 239000010949 copper Substances 0.000 description 10
- 102000004266 Collagen Type IV Human genes 0.000 description 9
- 108010042086 Collagen Type IV Proteins 0.000 description 9
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 9
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 102000004965 antibodies Human genes 0.000 description 9
- 108090001123 antibodies Proteins 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000003364 immunohistochemistry Methods 0.000 description 9
- 210000000056 organs Anatomy 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 101700033006 EGF Proteins 0.000 description 8
- 102100010813 EGF Human genes 0.000 description 8
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 230000001605 fetal Effects 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 102000012000 CXCR4 Receptors Human genes 0.000 description 7
- 108010061299 CXCR4 Receptors Proteins 0.000 description 7
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 7
- 102000003974 Fibroblast Growth Factor 2 Human genes 0.000 description 7
- 108090000379 Fibroblast Growth Factor 2 Proteins 0.000 description 7
- 102100010810 SALL4 Human genes 0.000 description 7
- 101700003526 SALL4 Proteins 0.000 description 7
- 229960000890 hydrocortisone Drugs 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N DATI Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 6
- 206010012601 Diabetes mellitus Diseases 0.000 description 6
- 108060003412 GRP Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 210000003459 Hepatic Duct, Common Anatomy 0.000 description 6
- 229940088597 Hormone Drugs 0.000 description 6
- KIUKXJAPPMFGSW-MNSSHETKSA-N Hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 6
- 102100009724 SLC4A2 Human genes 0.000 description 6
- 101710003068 SLC4A2 Proteins 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 6
- 108010075254 C-Peptide Proteins 0.000 description 5
- 210000002744 Extracellular Matrix Anatomy 0.000 description 5
- 229940099552 Hyaluronan Drugs 0.000 description 5
- 101700048573 KLF4 Proteins 0.000 description 5
- 102100006525 KLF4 Human genes 0.000 description 5
- 102000008993 Prospero homeobox protein 1 Human genes 0.000 description 5
- 108050000980 Prospero homeobox protein 1 Proteins 0.000 description 5
- 108010078762 Protein Precursors Proteins 0.000 description 5
- 102000014961 Protein Precursors Human genes 0.000 description 5
- 239000007759 RPMI Media 1640 Substances 0.000 description 5
- 210000000648 angioblast Anatomy 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000741 Bile Canaliculi Anatomy 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 210000000277 Pancreatic Ducts Anatomy 0.000 description 4
- 210000002966 Serum Anatomy 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000038129 antigens Human genes 0.000 description 4
- 108091007172 antigens Proteins 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000002440 hepatic Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 210000004500 stellate cell Anatomy 0.000 description 4
- 210000003855 Cell Nucleus Anatomy 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 210000002808 Connective Tissue Anatomy 0.000 description 3
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 3
- 210000001198 Duodenum Anatomy 0.000 description 3
- 101700024131 EXE4 Proteins 0.000 description 3
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 3
- 101700064732 FGF1 Proteins 0.000 description 3
- 102100007155 FGF1 Human genes 0.000 description 3
- 229960003082 Galactose Drugs 0.000 description 3
- 101700069518 ISL1 Proteins 0.000 description 3
- 102100001409 ISL1 Human genes 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 102100012248 KRT19 Human genes 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N Norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
- 101710027269 PECAM1 Proteins 0.000 description 3
- 102000037239 SLC10A2 Human genes 0.000 description 3
- 108091006529 SLC10A2 Proteins 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 3
- 229960001727 Tretinoin Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960005188 collagen Drugs 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000001086 cytosolic Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002255 enzymatic Effects 0.000 description 3
- 229960001519 exenatide Drugs 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 210000004923 pancreatic tissues Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 238000004450 types of analysis Methods 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 210000000577 Adipose Tissue Anatomy 0.000 description 2
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 2
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 2
- 102100004057 CYP3A4 Human genes 0.000 description 2
- 101710007540 CYP3A4 Proteins 0.000 description 2
- 108060005980 Collagenase family Proteins 0.000 description 2
- 102000020504 Collagenase family Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000006640 EC 2.3.2.2 Human genes 0.000 description 2
- 101700066372 ECM38 Proteins 0.000 description 2
- 210000003754 Fetus Anatomy 0.000 description 2
- 101700082072 GGT1 Proteins 0.000 description 2
- 101700080610 HELT Proteins 0.000 description 2
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 108010087745 Hepatocyte Nuclear Factor 3-beta Proteins 0.000 description 2
- WCDJCWGYYQTMGO-OAHLLOKOSA-N IC([C@](N)(C(=O)O)I)(C1=CC(I)=C(C(I)=C1)OC1=CC(I)=C(C(I)=C1)O)I Chemical compound IC([C@](N)(C(=O)O)I)(C1=CC(I)=C(C(I)=C1)OC1=CC(I)=C(C(I)=C1)O)I WCDJCWGYYQTMGO-OAHLLOKOSA-N 0.000 description 2
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 2
- 210000002660 Insulin-Secreting Cells Anatomy 0.000 description 2
- 101710026204 KRT19 Proteins 0.000 description 2
- 208000007903 Liver Failure Diseases 0.000 description 2
- 102100015262 MYC Human genes 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 210000000110 Microvilli Anatomy 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 108091008108 Myc family Proteins 0.000 description 2
- 102100017571 PDX1 Human genes 0.000 description 2
- 101700006931 SOX2 Proteins 0.000 description 2
- 102100018829 SOX2 Human genes 0.000 description 2
- 210000000603 Stem Cell Niche Anatomy 0.000 description 2
- 108010042606 Tyrosine Transaminase Proteins 0.000 description 2
- 102000016540 Tyrosine aminotransferase Human genes 0.000 description 2
- 241001442055 Vipera berus Species 0.000 description 2
- 229940091251 Zinc Supplements Drugs 0.000 description 2
- 101710038776 acyI Proteins 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000000735 allogeneic Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 210000004748 cultured cells Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000003897 hepatic stem cell Anatomy 0.000 description 2
- 230000001861 immunosuppresant Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 201000004044 liver cirrhosis Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 210000001316 polygonal cell Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001172 regenerating Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 230000000381 tumorigenic Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- 102100008450 AFP Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 230000035639 Blood Levels Effects 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 1
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 1
- 101710031273 GATD3A Proteins 0.000 description 1
- 101710031275 GATD3B Proteins 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N GMP group Chemical group P(=O)(O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC=2C(=O)NC(N)=NC12)O)O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 101700027355 HES1 Proteins 0.000 description 1
- 102100004111 HES1 Human genes 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000001974 Hyaluronidase Human genes 0.000 description 1
- 108010074224 Hyaluronoglucosaminidase Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 101700011716 IL2RG Proteins 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 206010062018 Inborn error of metabolism Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 102100013180 KDR Human genes 0.000 description 1
- 102100005748 KRT18 Human genes 0.000 description 1
- 102100013425 KRT7 Human genes 0.000 description 1
- 101710005528 KRT7 Proteins 0.000 description 1
- 102100013423 KRT8 Human genes 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 108010052014 Liberase Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 1
- 101700080605 NUC1 Proteins 0.000 description 1
- 210000004126 Nerve Fibers Anatomy 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 101710014878 PDHX Proteins 0.000 description 1
- 101710009214 PGGT1B Proteins 0.000 description 1
- 102100015423 PGGT1B Human genes 0.000 description 1
- 102100010938 PROX1 Human genes 0.000 description 1
- 101700078220 PROX1 Proteins 0.000 description 1
- 206010033628 Pancreatic insufficiency Diseases 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108060006898 RAG2 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100015788 SOX9 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L Zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000001427 coherent Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000002183 duodenal Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000007089 exocrine pancreatic insufficiency Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000003345 hyperglycaemic Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000002450 inherited metabolic disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- PXUQTDZNOHRWLI-OXUVVOBNSA-O malvidin 3-O-β-D-glucoside Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 PXUQTDZNOHRWLI-OXUVVOBNSA-O 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 238000002705 metabolomic Methods 0.000 description 1
- 230000001431 metabolomic Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 101700006494 nucA Proteins 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 108091005460 pancreatic and duodenal homeobox 1 protein Proteins 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 230000002980 postoperative Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000979 retarding Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- PORMUFZNYQJOEI-UHFFFAOYSA-N sumatriptan succinate Chemical compound OC(=O)CCC(O)=O.CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 PORMUFZNYQJOEI-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementation Effects 0.000 description 1
- 230000003319 supportive Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 201000011528 vascular disease Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/22—Zinc; Zn chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/80—Hyaluronan
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
- C12N2537/10—Cross-linking
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0678—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0679—Cells of the gastro-intestinal tract
- C12N5/068—Stem cells; Progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Abstract
Disclosed is a composition comprising mammalian multipotent stem/progenitor cells capable of differentiating into pancreatic, liver and biliary cells, wherein the cells are obtained from extrahepatic biliary tree tissue of a mammal, and the cell exhibits at least one of the following: (i) nuclear expression of telomerase protein; (ii) low to moderate levels of expression of pluripotency genes; (iii) expression of endodermal stem/progenitor surface markers; wherein the cell exhibits expression of endodermal transcription factors; wherein the cell lacks expression or expression of low and variable levels of lineage markers of mature liver, mature bile duct, or mature endocrine pancreas, such as hepatocytes, cholangiocytes, or islet cells; and wherein the cell lacks expression of markers for mesenchymal cells, endothelial cells or hemopoietic cells. xpression of telomerase protein; (ii) low to moderate levels of expression of pluripotency genes; (iii) expression of endodermal stem/progenitor surface markers; wherein the cell exhibits expression of endodermal transcription factors; wherein the cell lacks expression or expression of low and variable levels of lineage markers of mature liver, mature bile duct, or mature endocrine pancreas, such as hepatocytes, cholangiocytes, or islet cells; and wherein the cell lacks expression of markers for mesenchymal cells, endothelial cells or hemopoietic cells.
Description
MULTIPOTENT STEM CELLS FROM THE EXTRAHEPATIC BILIARY TREE
AND S OF ISOLATING SAME
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
This application claims ty from US Provisional Application 61/256,846, filed
October 30, 2009, incorporated herein by reference in its ty.
[0001A] This application is a divisional of New d Patent ation No. 709124, in turn
a divisional application of New Zealand Patent Application No. 622427, in turn a divisional
application of New Zealand Patent Application No. 600068, the entire contents of which are
herein incorporated by reference.
FIELD OF THE INVENTION
The present ion s generally to otent progenitor cells, including
multipotent stem cells, and cell populations comprising such progenitors or stem cells, in the
biliary tree, liver and pancreas. More particularly, the present invention relates to multipotent
progenitors or stem cells and cell populations sing such progenitors or stem cells derived
from ns of the extrahepatic biliary tree. It includes itions comprising same and
methods of identifying, isolating, maintaining, expanding and differentiating such cells and cell
populations in vitro and in vivo.
BACKGROUND OF THE INVENTION
Dead, dying, or dysfunctional cells are the cause of many known diseases, including
diabetes and mer's diseases. One method of treating these ailments has focused on
transplanting whole organs or parts thereof from donors to replace some or all of the functions of
the "diseased" cells. Though often successful in stemming or retarding the course of some
diseases, organ transplantation is accompanied by sizable morbidity/mortality, as are all major
surgical interventions, and survival of the transplant is dependent on chronic administration of
potent, systemic immuno-suppressants that often result in undesirable side effects. No matter the
success of these approaches, however, they are inherently limited by the availability of donors.
An alternate approach in "regenerative medicine" is the use of stem cells and
progenitors to repopulate whole organs, parts thereof, or at least their functions. Indeed, stem
cells can be injected or implanted with relatively minor surgical procedures, often with
negligible occurrence of adverse events. Because stern cells are not immunogenic (or are
minimally immunogenic), they e relatively little, if any, immunosuppressants for the initial
seeding of the cells.
Stem cells are rare cells requiring precise technologies to e and well-defined
conditions to propagate in vivo and in vitro. Therefore, there is an urgent need to establish
alternative and mentary sources of transplantable, fiinctional stem cells and progenitor
cells and tissue for clinical use.
SUMMARY OF THE INVENTION
According to one ment of the t invention, a composition comprising
mammalian multipotent stem/progenitor cells capable of differentiating into multiple
endodermal lineages (e.g., hepatic e, a biliary lineage, a pancreatic lineage, or a
combination thereof) is provided, wherein the cells are obtained from biliary tree tissue (e.g.,
any portion of the biliary tree, including the hilum, common hepatic duct, cystic duct,
common duct, common hepato—pancreatic duct gall bladder and liary glands or
progenitor cells or stem cells derived from the peribiliary glands) of a mammal, including a
human mammal, fetus, neonate, child (pediatric), adult, or a deceased person up to 72 hours
post mortem. Compositions comprising a population of cells comprising such mammalian
multipotent stem/progenitor cells and/or a population of mammalian cells enriched for such
multipotent stem/progenitor cells are also provided.
The multipotent stem/progenitor cells may express: (i) at least one marker tive
of early stage liver cell lineages (e.g., HNF6, HESI, CKl 9, albumin, or AFP); (ii) at least one
marker indicative of early stage pancreatic cell lineages (e.g, PDXl, PROXl, NGN3, or
insulin); and at least one marker selected from those in categories (a) ~ (0): (a) at least one
e marker found on stem/progenitor cells (e.g., CD133 (prominin), CD44H (hyaluronan
receptor), N—CAM, CXCR4, or EpCAM); (b) at least one transcription factor indicative of
endodermal stem/progenitors (e.g., SOX 9, SOX17, or , and (c) weak to moderate
expression a pluripotency gene (e.g, SOXZ, NANOG, KLF4, OCT4A or OCT4). In some
instances, the multipotent stem/progenitor cells can express one marker from each of
categories (i), (ii) and (a) ~ (c). The expression may be determined by endpoint and
quantitative RT-PCR assay and/or by immunohistochemistry of tissue in viva, of freshly
isolated cells, or of cultured cells
The otent cells may also express at least one of the following: (i) nuclear
expression of telomerase protein; (ii) low to moderate levels of expression of otency
genes; (iii) nuclear or clear expression of classic endodermal transcription factors (e.g.,
SOX17, SOX 9, FOXAZ, HESl, HNF6, PROXl, HNF3B (hepatocyte nuclear -3B,
FOXA2, SALL4 (Sal—like protein 4), PDX 1, NGN3, or combinations f); (iv)
expression of endodermal stem/progenitor surface markers; (v) lack of expression or
expression of low and variable levels of lineage markers of mature liver (P450-3A4,
transferrin, ne aminotransferase (TAT) and high levels of albumin; lineage markers for
mature bile duct comprise AE2, CFTR, secretin receptor, rins, or combinations
f), mature bile duct, or mature endocrine pancreas (e.g., n, glucagon,
somatostatin, amylase or combinations f); (vi) lack of expression of markers for
mesenchymal cells, endothelial cells or hemopoietic cells.
[0008A] In another embodiment of the invention, an isolated mammalian multipotent
rogenitor cell is provided wherein the cell is obtained in vitro from biliary tree tissue of
a mammal and wherein the cell expresses at least one of the ing:
(i) nuclear expression of telomerase protein;
(ii) low to moderate levels of expression of pluripotency genes;
(iii) nuclear or perinuclear expression of classic endodermal transcription factors;
(iv) expression of rmal stem/progenitor surface markers;
(v) lack of expression or expression of low and variable levels of lineage markers of
mature liver, mature bile duct, or mature endocrine pancreas, such as hepatocytes,
cholangiocytes, or islet cells; and
(vi) lack of expression of markers for hymal cells, endothelial cells or
hemopoietic cells.
In another embodiment of the ion, a method of obtaining, isolating, and/or
identifying a mammalian multipotent stem/progenitor cells capable of differentiating into
le endodermal lineages is provided, wherein the cells are obtained from biliary tree
tissue (e.g., the y tree tissue comprises hilum, common hepatic duct, cystic duct,
common duct, common hepato-pancreatic duct and gallbladder, or combinations thereof) of a
, the method comprising obtaining biliary tree tissue, and sequentially, and in any
order, or substantially simultaneously obtaining cells that are positive for: (i) at least one
marker indicative of early liver cell lineage stages (e.g., HNF6, HES1, CK19, albumin, or
AFP); (ii) at least one marker indicative of early pancreatic cell lineage stages (e.g., PDX1,
PROX1, NGN3, or insulin); and optionally, at least one marker selected from (a) - (c): (a) at
least one surface marker found on stem/progenitor cells (e.g., CD133 (prominin), CD44H
(hyaluronan receptor), N-CAM, CXCR4, or EpCAM); (b) at least one transcription factor
indicative of endodermal stem/progenitors (e.g., SOX 9, SOX17, or FOXA2), and (c) weak to
moderate expression a pluripotency gene (e.g., SOX2, NANOG, KLF4, OCT4A or OCT4). A
method of identifying and isolating a population of mammalian multipotent cells enriched for
the mammalian multipotent stem/progenitors is also provided.
According to the method, the basal medium may be any basal medium rich in
nutrients and with no copper and low calcium (below 0.5 mM), preferably supplemented with
insulin, transferrin/Fe, selenium, zinc, free fatty acids bound to serum albumin and,
optionally, high y lipoprotein. An example of a basal medium is RPMI 1640. The cells
may optionally be cultured on plastic alone or plastic coated with en IV, collagen III,
laminin, hyaluronans, other matrix components from embryonic, fetal, neonatal tissues or
combinations thereof. The cells are cultured for at least 24 hours and ably 7-21 days.
According to the method, the isolated cells are 80%, 90%, 95%, 95%, ably 100%
enriched for the stem cells of the present invention. The isolation may be carried out via
immunoselection technology (e.g., panning, magnetic bead selection, flow cytometry, or
combinations thereof) and/or selective culture conditions.
In yet another embodiment of the present ion, a method of ating
and/or expanding the novel ian multipotent stem/progenitor cells, or a population
comprising such cells or enriched for such cells or a partner cell thereof (e.g., mesenchymal
cells, angioblasts and stellate cell precursors), comprising: culturing the cells on plastic or
hyaluronans, or optionally on plastic coated with type III or IV collagen or hyaluronan or
other matrix component derived from fetal, neonatal, or nic tissue and in a basal
medium containing no copper, low calcium (<0.5 mM), insulin, transferrin/Fe, a mixture of
free fatty acids bound to serum albumin, and optionally, high density lipoprotein.
In still yet another embodiment of the ion, a method of lineage restricting the
novel multipotent stem/progenitor cells to adult liver cell fates is provided. The method
comprises (a) obtaining a cell suspension comprising mammalian multipotent
stem/progenitor cells capable of differentiating into multiple endodermal es, wherein
the cells are obtained from biliary tree tissue of a mammal; (b) ing the cell suspension
into a hydrogel comprising hyaluronan or hyaluronan combined with other matrix
components (e.g., type IV collagen, laminin, or both); and (c) ing the cell suspension in
basal medium supplemented with copper, calcium (≥0.5 mM), insulin, transferrin/Fe, bFGF,
hydrocortisone, glucagon, galactose, tri-iodothyroxine (T3), epidermal growth factor (EGF),
hepatocyte growth factor (HGF), high density otein, and a mixture of free fatty acids
bound to albumin, for a time sufficient to allow their differentiation into liver cells.
In still yet another embodiment of the invention, a method of lineage restricting the
novel multipotent stem/progenitor cells to adult pancreatic cell fates is provided. The method
comprises (a) ing a cell suspension comprising the mammalian multipotent
stem/progenitor cells ian multipotent stem/progenitor cells capable of differentiating
into multiple endodermal lineages, wherein the cells are ed from y tree tissue of a
mammal; (b) embedding the cell suspension into a hydrogel sing hyaluronans or
hyaluronans combined with other matrix components; and (c) culturing the cells in a basal
medium supplemented with copper, calcium (≥0.5 mM) , B27, ascorbic acid, insulin,
transferrin/Fe, bFGF, cyclopamine, retinoic acid , exendin 4, high density lipoprotein, and a
mixture of free fatty acids bound to albumin; and lacking hydrocortisone for a time sufficient
to allow their differentiation into pancreatic cells.
In still yet another embodiment of the invention, a method of lineage restricting the
novel multipotent stem/progenitor cells to adult biliary cell fates is provided. The method
comprises (a) obtaining a cell sion comprising the mammalian multipotent
stem/progenitor cells mammalian otent stem/progenitor cells e of differentiating
into multiple endodermal lineages, wherein the cells are obtained from biliary tree tissue of a
mammal; (b) ing the cell suspension into a hydrogel comprising hyaluronans or
hyaluronans in combination with other matrix components (e.g., type I collagen); and (c)
culturing the cells in a basal medium supplemented with copper, calcium (≥0.5 mM), n,
transferrin/Fe, hydrocortisone, bFGF, vascular endothelial cell growth factor (VEGF),
hepatocyte growth factor (HGF) , high density lipoprotein, and a mixture of free fatty acids
bound to albumin, for a time sufficient for their entiation into cholangiocytes.
In still yet another embodiment of the invention, a method of differentiating cells
in vivo is provided, comprising transplanting the mammalian otent stem/progenitor
cells, or populations comprising such cells or enriched for such cells, in vivo as cell
suspensions or as implants or grafts, with or without prior lineage restriction under
appropriate culture conditions, into the liver where they differentiate to liver tissue.
In still yet another embodiment of the ion, a method of entiating cells
in vivo is provided, comprising transplanting the mammalian multipotent stem/progenitor
cells of Claim 1, or populations comprising such cells or enriched for such cells, in vivo as
cell suspensions or as implants or grafts, with or without prior lineage restriction under
appropriate culture ions, into the bile duct where they differentiate into biliary tree
tissue.
In still yet another embodiment of the invention, a method of differentiating cells
in vivo is provided, comprising lanting the mammalian multipotent stem/progenitor
cells of Claim 1, populations comprising such cells or enriched for such cells, in vivo as cell
suspensions or as implants or grafts, with or without prior lineage restriction under
appropriate culture conditions into the pancreas, under the kidney capsule or into the
epididyrnal fat pads, where they differentiate into functional pancreatic tissue.
In this respect, before explaining at least one embodiment of the invention in detail,
it is to be understood that the invention is not limited in its application to the details of
construction and to the arrangements of the components set forth in the ing description
or illustrated in the drawings. The invention is capable of embodiments in addition to those
bed and of being practiced and carried out in s ways. Also, it is to be understood
that the phraseology and terminology ed herein, as well as the abstract, are for the
purpose of description and should not be regarded as limiting.
[0018A] Throughout this specification the word "comprise", or variations such as
"comprises" or "comprising", will be tood to imply the inclusion of a stated element,
integer or step, or group of elements, integers or steps, but not the exclusion of any other
element, integer or step, or group of elements, rs or steps.
As such, those skilled in the art will appreciate that the conception upon which this
disclosure is based may y be utilized as a basis for the designing of other structures,
methods and systems for carrying out the several purposes of the present ion. It is
important, therefore, that the claims be regarded as including such equivalent constructions
insofar as they do not depart from the spirit and scope of the present invention.
(followed by page 6)
BRIEF DESCRIPTION OF THE DRAWINGS
Figure l is a schematic diagram depicting a otent biliary stem cell of the
present invention having the ty to differentiate into several types of endodermal tissues.
All of the cells express “endodermal” (E) transcription factors (e. g. SOX 9, SOX 17,
FOXAZ) and other markers of stem/progenitor populations ( surface antigens such as CD133,
CD44H, EpCAM, CXCR4, NCAM). Lineage restriction results in various adult fates
including liver, pancreas, and biliary tree.
Figure 2 is a schematic diagram of the biliary tree showing its connections with liver,
pancreas and duodenum. Sites at which high numbers of liary glands, the stem cell
niches of the biliary tree, may be found are indicated by a star.
Figure 3 is a composite of images of histology and immunohistochemistry of
different regions of the biliary tree and that were used to identify s and also the
numbers and sizes of peribiliary glands throughout the y tree. (a) Distribution and
characterization of peribiliary glands (PBGs) in the extrahepatic biliary tree. PBGs are
present in the duct walls of the biliary tree and are sites for y tree stem/progenitors. A
survey was done (n: 5 human biliary trees examined) of the numbers and sizes of the
peribiliary glands at varying sites within the biliary tree, of marker profiles of the PBGs. The
density of PBGs, expressed as surface occupied by PBGs acini/total area as evaluated by
g analysis; the number and circumference were histologically analyzed in the ent
sites of the human extrahepatic biliary tree. The -pancreatic ampulla showed the
highest density and number of PBGs; roughly equal numbers were found in the cystic duct
and hilum; less were found in bile duct; and none in gallbladder. *p< 0.01. Original
magnification x10, 1): histochemistry of PBGs in situ. The PBGs are positive for
CK7, CK19, NCAM, CD133, insulin, EpCAM, SOX9, SOX 17 and PDXl but negative (or
very low levels) for albumin. Variation in these early lineage markers (6. g. albumin) are seen
among various peribiliary glands (see Figure 7 for evidence with respect to albumin).
Original magnification x 40.
Figure 4 shows that the stem cells are located primarily within the peribiliary glands
(PBGs). Note that there is ility within a single peribiliary gland in the expression of the
stem cell markers, which in this case is PDXl. The red arrows indicate the nuclei of cells
expressing the transcription factor; the black arrows te ones not expressing it.
Figure 5 shows SOX17 (A) and PDXl (B) along with EpCAM (green) and nuclei
stained blue with 4',6~diamidino—2-phenylindole (DAPl) in peribiliary glands of cystic duct.
Figure 6 provides immunohistochemistry data on human biliary tissue and showing
expression of EpCAM SOX 9, and SOXl 7 in peribiliary glands in cystic duct and hilum.
Figure 7 provides a summary of the key properties of the multipotent Biliary Tree
Stem Cells. These include surface markers of stem/progenitors; transcription s typical
of endodermal progenitors; variable expression of early lineage stage markers of liver, biliary
tree, and pancreas; and in Figure 8 the weak to te expression of pluripotency genes.
Representative RT—PCR assays for hepatic hilum indicate a broad repertoire of endodermal
transcription factors (SOX 9, SOX l7, FOXAZ, PDXl, NGNS, etc.) and c
stem/progenitor surface markers (e.g. EpCAM, NCAM, CXCR4, CD133).
Figure 8 shows RT-PCR data indicating expression of pluripotency genes by cystic
duct and hilum . Their weak to moderate expression provides additional evidence for
the ability of the y Tree Stem Cells to self-replicate. Pluipotency genes are ones found
expressed in embryonic stem (ES) cells and ones able to yield induced pluripotent stem (iPS)
cells if varying combinations of these genes are transfected into c cells. At least 5
genes have been identified: OCT 4, SOXZ, NANOG, KLF4 and c—MYC. Weak to moderate
levels of expression occur in biliary tree tissue and in isolated Biliary Tree Stem Cells for
OCT 4, SOXZ, NANOG, KLF4, but not c—MYC.
Figure 9. Gallbladder does not n peribiliary glands (as shown also in Figure
3). However, cells expressing some of the stem/progenitor transcription factors and surface
markers are present in gallbladder cells. Note that the brownish stain indicative of expression
of the marker assayed (EpCAM or PDXl) is present in the cells at the surface of the
adder.
Figure 10 shows histochemistry data on gallbladder tissue that has n9
peribiliary glands. (a,c,d). The cells are positive for EpCAM (green) and have perinuclear
staining for endodermal transcription factors (shown is SOX l7-red). (b) the cells also
s PDXl (pink) and are markedly proliferative as ted by Ki67 staining (green).
Figure 11. Stem/progenitor cell colonies from biliary tree tissue. Cells were isolated
and cultured in serum~free Kubota’s Medium and on culture plastic. Three distinct colony
types, Types 1-3, were observed under these conditions that are not permissive for mature
cells but rather select for endodermal stem/progenitors. lmmunohistochemical staining
indicates expression for specific genes indicated by text in the color indicated for the marker.
All ns are stained with iamidinophenylindole (DAPI) providing a blue color
indicating nuclei. Colony type I (a) aggregates of cells strongly expressing EpCAM,
NCAM, and ASBT. The cells grew slowly (with divisions every 3-4 days or longer). gm
age 2 cells (b) with a phenotype closely similar to that of thSCs and with 100% of the cells
expressing EpCAM, NCAM but none expressing AFP (with divisions every 36—40 hours).
Colony txge 3 (c) are sed of undulating, swirling cells with EpCAM expression at the
edges but not interiors of the colonies and with high levels of sion of SOX 17, PDXl,
or SOX 9 in the interior cells (with divisions every 36-40 hours). The magnification for all of
the images is 20X. Pictures are entative of findings from more than 10 experiments in
which the colonies were monitored for 4-8 weeks.
Evidence of a relationship between cells of colony types 2 and 3 is shown in a low
magnification (4X) image (d). It is unknown if one is a precursor of the other. RT-PCR
assays (e) indicate the expression of diverse genes in the colonies from cystic duct versus
from gall r. The RT-PCR assays from the two tissues are quite r, but those from
cystic duct have weak expression of albumin and n, two genes not expressed by
progenitor cells which were obtained from the gallbladder and growing in serum~free
’s Medium and on plastic.
Figure 12. The Biliary Tree Stem Cells, especially those of type 2 and 3 colonies,
expand ly for months resulting in colonies of cells with stable expression of
stem/progenitor markers. This is partial evidence for self—replication of the cells; additional
evidence is provided by the expression of pluripotency genes (Figure 8). Here is shown a
type 3 colony after a month in culture with maintenance of expression of PDXl(orange/red)
in the cells that are at the center of the colony and with EpCAM (green) expressed only at the
edges of the colony, sites at which there is slight differentiation. DAPI staining (blue)
indicates the nuclei of the cells.
Figure 13. Phase micrograph of a biliary tree stem cell colony in culture for more
than 8 weeks on culture plastic and in serum—free Kubota’s . The colony was
initiated from 1-2 cells derived from adult human biliary tree tissue. To estimate the number
of cells within the , magnified images were prepared from multiple regions of the
colony (representative ones are indicated in the rectangular areas demarcated by colored
outlines) and these areas imaged with Metamorph software and used to obtain cell numbers.
The sampling of regions resulted in estimates of more than 500,000 cells in the colony. From
fetal biliary tree tissue, we e routinely >50 such colonies; from cystic duct and hilum
tissue from adults, we routinely obtain >100 such colonies.
Figure 14. Location of transcription factors (or of telomerase protein) in tissue (in
situ) or in cultures of Biliary Tree Stem Cells. Immunohistochemistry revealed that the
ription factors and telomerase n were present intranuclearly in some cells and
perinuclearly or cytoplasmically in others. The significance of this is not known, though we
hypothesize that nuclear zation implicates an active factor and perinuclear or
cytoplasmic location might be a storage form. In these images, SOX 17 is expressed within
the nucleus of some, but not all, of the cells of a peribiliary gland in vivo (in situ data) and is
sed within the nucleus of all of the Biliary Tree Stem Cells in culture on plastic and in
Kubota’s Medium. In the images of the cultures, the nuclei are blue from staining with
DAPI; some of the cells express EpCAM (green); but all have intranuclear zation of
SOX 17 (red). When the images are merged, the nuclei appear pink in color (merged blue
and red ).
Figure 15. Type 3 colony of Biliary Tree Stem Cells demonstrating both nuclear and
perinuclear localization of the transcription factor, SOX 17 (red/pink). The cells at the
ter of the colony are positive for EpCAM (green). The nuclei are stained blue with
DAPI
Figure 16. In situ staining of gallbladder cells demonstrating only perinuclear and
cytoplasmic staining of SOX 17 (red/orange). The cell membranes are positive for EpCAM
(green), and the nuclei are stained blue with DAPI.
Figure 17. Multipotentiality of the Biliary Tree Stem Cells. Effects of Hormonally
Defined Media (HDM) alone on differentiation to an cytic or cholangiocytic fate. The
stem cells remain indefinitely as stem/progenitors if cultured on plastic and in Kubota’s
Medium. They will differentiate s an adult fate if the medium is changed to a
hormonally defined medium (HDM) tailored for an adult fate. They will entiate faster
and more efficiently to an adult fate if the HDM is used in combination with plating the cells
on or embedding them into forms of extracellular matrix (Figures . In these studies
are shown representative data indicating the effect of a c HDM on the differentiation of
the biliary tree stem/progenitors towards an hepatocytic ) versus cholangiocytic
(HDM—C) fate.
[003 8] Biliary tree stem/progenitors from colonies maintained under eplication
conditions (culture plastic and serum-free Kubota’s Medium or its equivalent) were
transferred either in HDM tailored for either hepatocytes (HDM—L), the upper row of images,
or for cholangiocytes (HDM-C), the lower panel of images. HDM-L Effects.:
Immunofluorescence (a) after 7 days. Cells were diffusely positive for CK] 8 (red) and/or
albumin (blue-green). Magnification: 20X. Semi-quantitative data (c) comparing the numbers
of hepatocytes (CK18+/albumin+ cells) under self—replication conditions (score: 0) versus in
HDM-L (score: 2.2 i 0.8), findings that translate to >20% of the cells having lineage
restricted to an hepatocytic fate. HDM-C effects:. Immunofluorescence (b) after 7 days.
Cells were diffusely positive for CK7, secretin receptor (SR), and CFTR. They co-expressed
CK7/SR and CK7/CFTR. Original cations are 20X except for c4 and c5 that are 40X.
Semi-quantitative estimate (c) of % of SR+/CFTR+ cells in the conditions for self—replication
(0.2 fl: 0.4;<5% ofthe cells) versus in the HDM—C (3 i 0.7 which equates to over 30 % of the
cells lineage restricting to giocytes.
Figure 18. Multipotentiality of the y Tree Stem Cells. Effects of Hormonally
Defined Medium tailored to pancreas (HDM—P) alone on differentiation to a pancreatic fate.
HDM—P Effects: Immunofluorescence for pancreatic markers after 7 days of culture in
HDM—P. At the periphery of the colonies, cell aggregation and condensation occurred to
form Islet-like structures (a—d) containing ide (a,b), PDX—l (c) and n ((1).
Undifferentiated cells (EpCAM+ cells) were found within the colony centers (e). Original
Magnifications: 20X. The number of islet—like structures (f) found in the conditions for self
replication (1 5:07; <10% of the cells) were much lower than that in the HDM-P (3.8 5:13;
~40% of the cells). The levels of C-peptide (g) in ng/ug of protein under glucose
concentrations found in all RPMI 1640 formulations (1 1.1 mM) for a 2 hour incubation in the
conditions for self-replication was 4.5 :t 2.25 versus 12.3 i 1.9 ng/ Mg in the HDM-P
. The
data are expressed as Means i Standard Error, N=4; *p < 0.05. (h) Glucose ated c—
peptide secretion was observed in the HDM-P controls with the levels of the c-peptide in the
medium, in ,ug/l, at 1.10 i 0.32 ug/l in low levels of glucose (5.5 mM) to 1.92 i 0.43 ug/l in
high e (22 mM) n=7; *p < 0.01.
Figure 19. Multipotentiality of the Biliary Tree Stem Cells. tative (q)-RT—PCR
analyses for effects of medium alone. The assays were done on biliary tree stem cell cultures
maintained under self—replication conditions (culture plastic and ’s Medium) versus in
a serum-free, hormonally defined medium (HDM ~L or HDM-C or HDM-P) alone tailored
for hepatocytes, giocytes versus atic cells. The mRNA relative expression
levels were calculated by ranking the normalized ACt values against the geometric mean of
the three most stable housekeeping genes. The data are indicated plus or minus (5:) standard
deviation. The significance levels for each of these was *p<0.05. n= the number of
experiment done.
Figure 20. Multipotentiality of the Biliary Tree Stem Cells. Effects of both an HDM
and extracellular matrix components on the differentiation of the Biliary Tree Stem Cells.
The biliary stem cells were cultured on plastic and in Kubota’s Medium or its equivalent
(self-replication conditions) for over a month ing in colonies such as the one in (a).
Such a representative colony was dispersed, and the cells were transferred to one of 3
differentiation conditions, presented in a 3—dimensional (3-D) format and comprised of an
HDM + matrix components tailored for the desired adult fate: one for cholangiocytes (b),
hepatocytes (c), or for pancreatic B—cells (d) They were ined for up to 9 days in culture
and then assayed for —specific fates which indicated that these Biliary Tree Stem Cells
can lineage restrict to multiple adult fates (here provided the es of cholangiocytes,
hepatocytes or pancreatic B—cells) depending on the culture conditions. Row izone
(DTZ) staining. (indication of pancreatic oz and 6 .D=days in culture; Glu=glucagon; C-
F: C—peptide, indicative of insulin secretion
Figure 21. ission electron microscopy of Biliary Tree Stem Cells under self
replication conditions (a—b) vs ones in the 3-D differentiation conditions to yield mature liver
cells (c—d).Large and polygonal cells were present and cell nuclei display one or more
nucleoli. (c) Adjacent cells form well-defined bile canaliculi (arrows). Bile canaliculi are
closed by junctional complexes (arrowheads). Few microvilli are present in the lumen. (d).
Thus, the cells were able to mature to adult hepatocytes and intrahepatic giocytes.
Bar=2ptm
Figure 22. Proof of multipotentiality of the biliary tree stem/progenitors as given by
by quantitative (q)—RT—PCR analyses on cultures under self-replication versus 3-D
differentiation conditions. a. The biliary tree rogenitors were cultured in Kubota’s
Medium and on c for 2 months (self-replication conditions). The es were either
maintained in those conditions and thereby ng biliary stem/progenitor cells (BP) or
transferred into the 3—D Differentiation conditions for hepatocytes (B—L), cholangiocytes (B-
C) or pancreatic islets (BF), and all were cultured for an additional 2 weeks. The cultures
were then prepared for qRT-PCR analyses of genes relevant to each of the adult fates. The
data were ed as histograms in which the levels of expression of the genes in the self-
replication conditions (BP) were given the value of 1.0, and the value of each gene in cells
after differentiation to an adult fate was given as the fold change relative to that in BPS. The
asterisk on some of the histograms indicates those of statistical significance (p<0.0l or
p<0.00l). N=2, each experiment with triplicate samples. BP = y rogenitors; B-C
= cells lineage restricted to bile duct (cholangiocytes); B-L : cells lineage restricted to liver
(hepatocytes); B—P 2 cells lineage restricted to pancreas (islets). The genes assayed were
GGTI = gamma glutamyl transpeptidase—l; AE2 = anion exchanger 2; CFTR = cystic
fibrosis transmembrane tance tor; HNF4a = hepatocyte nuclear factor 4A; AFP
= alpha-fetoprotein; ALB: albumin; TF: transferrin; TAT = tyrosine aminotransferase;
CYP3A4 = cytochrome P450 3A4; pdx1= Pancreatic and duodenal homeobox 1 ; ISL-1 =
ISL LIM homeobox 1; NGN3 = neurogenin 3; INS = insulin; GCG = glucagon.
Figure 23. Multipotentiality of the Biliary Tree Stem Cells as indicated by in vivo
studies: Hepatic Fate. y tree stem cells were maintained in culture under self—
replication conditions (Kubota’s Medium or its equivalent and e plastic) and then were
ed into the livers of immunocompromised, adult mice with quiescent livers (that is, no
liver injury was induced). Liver sections prepared from the mice were then analyzed by
immunohistochemistry for human specific markers indicative of cytes. In this image,
the section was stained for Dako’s Anti human Hepar-l. The sections revealed that one can
fy 6.52 i 2.5% of the total area occupied by human hepatocytes positive for human
Hepar-l, a classic hepatocyte marker.
Figure 24. Multipotentiality of the biliary tree setm cells as indicated by
lantation in vivo: Biliary Tree Fate. Biliary tree stem cells were maintained in culture
under self-replication conditions (Kubota’s Medium or its equivalent and culture plastic) and
then were injected into the livers of immunocompromised, adult mice with quiescent livers
(that is, no liver injury was induced). Liver sections prepared from the mice were then
analyzed by immunohistochemistry for human specific markers tive of cholangiocytes.
Dako’s anti-human CK7, a marker of cholangiocytes, was found on an average of 12.7 i
.5% of all giocytes. In comparing the evidence for human cholangiocytes in small
versus large bile ducts, it was found that ~ 14.92 i 5.9% cells in the large bile ducts and ~
.02 i 1.95% of the cells in small bile ducts were positive for human CK7.
Figure 25. Multipotentiality of the biliary tree setm cells as indicated by
transplantation in vivo: atic Fate. Biliary tree stem cells were maintained in culture
under eplication conditions (Kubota’s Medium or its equivalent and culture plastic) and
then were ed into the epididymal fat pads (EFP) of male Balb/C Rag2'f'i/Il2rg'/' mice.
Each mouse was injected with 200—400 neoislets, cell aggregates of Biliary Tree Stem Cells
lineage restricted for 7-14 days towards a pancreatic islet fate in the 3—D differentiation
conditions of an HDM-P plus a hydrogel containing hyaluronan, type IV collagen and
laminin. Each neoislet was comprised of more than 1000 cells. The control mice were
transplanted with Matrigel Without cells. The mice were monitored daily for glucose levels
and were hyperglycemic (600- 750 mg/dl) for about 3 months. By 3 months, the glucose
levels in the transplanted mice had dropped to levels that were less than half that in the
controls. Glucose tolerance tests were performed at postoperative day 68 and 91 and showed
cant blood levels of human ide in experimental mice, and these levels were
regulatable by glucose.
ED DESCRIPTION OF THE INVENTION
The present invention stems from the heretofore unexpected discovery of a
multipotent stem or progenitor cell, and cell populations comprising such multipotent stem or
progenitor cells, found within the biliary tree and having the capacity to entiate into
multiple endodermal lineages, including liver, pancreas, and biliary tree (Figure 1). In the
st of clarity for this application, the term “Biliary Tree Stem Cell” will be used herein to
refer to the inventive ian multipotent stem or progenitor cell, cell tions
comprising such inventive cells, and cells populations enriched for the inventive cells.
[0048} The novel, multipotent Biliary Tree Stem Cells can be isolated from any portion of
the y tree tissue but are found at especially high numbers in the peribiliary glands and at
the branching points of the tree, which are indicated by stars on the schematic image of
Figure 2. The stars found on the smallest ing terminals within the liver refer to the
canals of Hering, the stem cell niche for intrahepatic hepatic stem cells. The Biliary Tree
Stem Cells are precursors to the intrahepatic hepatic stem cells.
Cell Sourcing-Biliary tree
The biliary tree or extrahepatic biliary tree system is comprised of a series of ducts
connecting the duodenum to the liver and to the pancreas and including the gallbladder (se
schematic in Figure 2). Throughout the biliary tree, within the duct walls, are peribiliary
glands (Figures 3-1 1), which may be found in particularly high numbers at the branching
sites such as the hilum, common hepatic duct, cystic duct, common duct, common hepato-
pancreatic duct and ldder. Fluids from liver or from ventral pancreas are emptied into
the duodenum Via the Papilla of Vater. This entire group of structures, ing the
gallbladder, is referred to herein as the biliary tree.
All of the biliary tree (e.g., the hilum, common hepatic duct, cystic duct, common
duct, common hepato~pancreatic duct and gallbaldder) have walls composed of dense,
fibrous connective tissue and a lumen lined by a layer of highly columnar biliary epithelium
supported by a conventional nt membrane. Smooth muscle cells are dispersed along
the ducts particularly near the Papilla of Vater. Blood vessels, nerve fibers and some
lymphoid cells are found occasionally in the duct walls. Peribliary glands are found along the
entire length of the biliary tree and in especially high numbers in the common -
pancreatic duct and the hilum, common hepatic duct, cystic duct, common duct and
gallbladder. Figures 3-7.
The gallbladder has different features (Figures 9, 10). The lumen is lined by
columnar epithelia, a proper muscle layer and subserosal connective tissue. No peribiliary
glands are present in the gallbladder (Figures 3, 9). However, the gallbladder does have cells
with overlapping phenotypes to those of the biliary tree stem cell populations found within
the peribiliary glands are transit amplifying cells and/or committed progenitors.
The cells of the present invention may be isolated from biliary tree tissue of any stage
of development. Thus, the instant invention may be practiced with fetal, al, pediatric
or adult tissue, including tissue from recently deceased individuals (preferably, within 10
hours, but the inventive cells remain viable for isolation of up to 72 hours post mortem). In
fact, the y tree tissue is unique in that it is readily available from fetal, pediatric and
adult donors. Furthermore, the present invention may be ced with tissue from liver and
pancreas organs obtained for, but then rejected for, transplantation, or from biopsy tissue,
from resection tissue.
As well, the teachings herein are not limited or able to any one mammalian
species. In fact, it should be understood that the examples ed herein are merely
exemplary and should not be construed as limiting. The instant invention, in this way, is not
d by its mammalian source for y tree tissue. Mammals from which the Biliary
Tree Stem Cells may be derived include, but are not limited to, humans, rodents (e.g., rats,
mice, hamsters), rabbits, cows, horses, pigs, sheep, dogs and cats. Preferably, the Biliary
Tree Stem Cells are derived from humans for use in humans.
As noted, the novel class of Biliary Tree Stem Cells of the invention can be
differentiated into multiple endodermal fates. Indeed, the Biliary Tree Stem Cells of the
present invention may be induced to differentiate into mature cell types of several
endodermal es including liver, y tree and pancreas. Figures 17—25.
Samples of y tree tissue can be dissected surgically from livers or as
obtained for and then rejected for transplant due to reasons such as steatosis; anatomical
abnormality, or major vascular disease; or they can be obtained from resection material.
They can be from gallbladders removed for various reasons. The biliary tree tissue can be
d from the connective tissue of the n. The tissue is then divided into segments
and processed further. Segments that are especially rich in the Biliary Tree Stem Cells
include: the hilum, common hepatic duct, cystic duct, common duct, common hepato-
pancreatic duct and adder. Each part can be further dissected into pieces cutting along
the longitudinal diameter.
The y Tree Stem Cells have been shown to give rise to multiple rrnal
fates including liver, biliary tree and pancreas cells es 17-25). The y Tree Stem
Cells express telomerase protein; low to te levels of pluripotency genes ( Nanog,
SOX2, KLF4 and OCT4—Figure 8); classic endoderrnal transcription factors (e.g., SOX17,
SOX 9, FOMZ, HNF6, PROXl, HNF3B (hepatocyte nuclear factor-3B (a.k.a. FOXAZ),
SALL4 (Sal-like protein 4), PDX 1 and NGN3); endoderrnal surface markers (e.g.,
CD326/Epithelial cell adhesion molecule or EpCAM; CD56/Neuronal cell adhesion molecule
or NCAM); CXCR4; and several stem/progenitor genes (e.g., CD44H—- hyaluronan
receptors, and CD133, also called prominin). Figures 7, 8, 9, 13.
rmore, ostensibly due to their multipotency, the Biliary Tree Stem Cells express
low and variable levels of early lineage markers of the liver (e.g., HNF6, HESl, FOXAZ, and
ly albumin), bile duct (e.g., cytokeratin 19), and endocrine pancreas (e.g., PDXl,
NGN3, SALL4, insulin). Figures 7, 22
Notably, the Biliary Tree Stem Cells express the transcription s PDXl and
NGN3 (Figure 3, 4, 7, 11), known to be essential for development of the pancreas and the
endocrine pancreas, respectively. However, the Biliary Tree Stem Cells do not express or
only weakly express mature markers of Cholangiocytes (e.g., secretin receptor, aquaporins),
hepatocytes (e.g., albumin, tyrosine aminotransferase or TAT, transferrin, “late” P450s such
as P450—3A4) or islet cells (e.g., glucagon, somatostatin, amylase or high levels of insulin)
(Figures 3, 7, 13). They do not express at all markers for mesenchyrnal cells (e.g., CD146,
desmin), endothelial cells (e.g., VEGF receptor, CD31, Van Willebrand Factor) or
hemopoietic cells (e.g., CD45). The n of expression of the antigens is stable throughout
the life of the cultures as long as they are maintained under self—replication conditions
consisting of Kubota’s Medium or its equivalent and with a substratum of culture plastic or
hyaluronans.
These sion patterns can be determined using endpoint and tative (q)—RT—
PCR assays and by immunohistochemistry of tissue in viva, of freshly isolated cells, or of
cultured cells. The co-expression in cells within the same peribiliary gland of multiple
markers of endodermal stem/progenitors (e. g., SOX 9, SOX17, PDXl, NGN3, FOXAZ) is a
unique and sing feature that is distinctive from the findings with respect to embryonic
stem (ES) cells undergoing lineage restriction to pancreas and in which these transcription
factors are ed sequentially, but not all at the same time. Furthermore, the expression of
these transcription factors is absent in mature y cells at the lumenal surface of the bile
ducts.
The Biliary Tree Stem Cells of the present invention, as explained above, are
progenitors to mature endodermal tissues and share markers with cells of the multiple tissues
to which they can give rise including liver, biliary tree, and pancreas.
In addition to their relative expression levels, the cellular zation of telomerase
and of the ription factors (e.g., SOX 17, PDXI) sed within the Biliary Tree Stem
Cells changes from a nuclear localization to a perinuclear/cytoplasmic localization during
maturation (See Figure 7 and also Figures 14—16). Within a single peribiliary gland, one
observes some cells with nuclear and some cells with perinuclear localization or with no
expression of the given marker (Figures 4, 6, 7, 14). t being held to or bound by
theory, intranuclear localization is associated with more primitive cells than those with
perinuclear localization of the ription factor(s). The latter cells are assumed to be
transitioning into a later lineage stage. Alternatively, the perinuclear localization could
indicate that the (s) is in an inactive storage form that can be translocated to the nucleus
under appropriate regenerative s.
The instant ion provides techniques for the isolation and propagation of Biliary
Tree Stem Cells. The stem cell populations from human biliary tree tissue were identified by
culture selection technologies but can be isolated also by immunoselection technologies (e.g.,
flow cytometry, panning, magnetic bead isolation). Alternatively, or in addition to
immunoselection, the Biliary Tree Stem Cells of the present invention may be isolated by
virtue of tissue culturing conditions. For example, cell suspensions prepared from the biliary
tree tissue may be plated onto plastic or hyaluronans. In other embodiments, the plastic is
coated optionally with en IV, collagen III, laminin, hyaluronans, other matrix
ents found in embryonic/fetal tissues, or combinations thereof.
The medium used for culture selection, serum—free Kubota’s Medium or its
equivalent, is strongly selective for the survival and proliferation of the Biliary Tree Stem
Cells and their partner mesenchymal cells, angioblasts and te cell precursors, but is not
selective for mature cells of the biliary tree. The essence of this medium is that it is any basal
medium containing no copper, low calcium (<0.5mM), insulin, transfenin/Fe, free fatty acids
bound to purified albumin and, optionally, also high density lipoprotein.
’s Medium or its equivalent is serum—free and contains only d and
defined mix of hormones, growth factors, and nutrients. More specifically, the medium is
comprised of a serum—free basal medium (e.g., RPMI 1640) containing no copper, low
calcium (< 0.5 mM) and supplemented with insulin (5 ug/ml), transferrin/Fe (Sug/ml), high
density lipoprotein (10 ug/ml), selenium (10'10 M), Zinc (10”12 M), namide (5 ug/ml),
and a mixture of free fatty acids bound to a form of purified albumin. The detailed methods
for the preparation of this media have been published elsewhere, e.g., Kubota H, Reid LM,
Proceedings of the National y of Sciences (USA) 2000; 97:12132—12137, the
disclosure of which is incorporated herein in its entirety by reference.
These conditions yield es of Biliary Tree Stem Cells that grow rapidly for
weeks (more than 8 weeks), with eration rates ted at a on every 36—40 hours.
Figures 11—13. The cultures are able to remain stably as stem/progenitors for more than 8
weeks (Figure 13), evidence that they are undergoing self—replication. This evidence for
self-replication is further supported by the finding of weak to moderate levels of expression
of pluripotency genes. Figure 8. The number of colonies obtained is highest in cultures
from the portions of the biliary trees having large numbers of peribiliary glands and
intermediate in those from sites other than the branching points of the biliary tree or from gall
bladder with no peribiliary glands.
Lineage ction and Differentiation to Adult Fates
{0066] Consistent with the multipotency of the Biliary Tree Stem Cells, if a colony is
maintained for weeks (e,g., over a month in culture) under self-replication conditions and
then the medium d to a serum—free, hormonally defined medium (HDM) tailored for a
specific adult cell type, the cells will partially differentiate towards the designated adult cell
type (Figures 17-19). In an HDM for liver (HDM-L), 20—30 % of the cells acquired
expression of cytokeratin 8 and 18 and albumin, whereas in an HDM for cholangiocytes
(HDM—C), over half of them matured to cells expressing secretin receptor and CFTR. Figure
17. The level of expression of human albumin in the es in HDM—L and the expression
of secretin receptor in those in HDM—C were significantly higher than those in Kubota’s
Medium or its equivalent replication conditions) in assays using quantitative RT-PCR
(Figure 19).
Partial lineage restriction of the cells towards a pancreatic islet fate ed if the
Biliary Tree Stem Cells were cultured in an HDM for pancreas (HDM-P). Figure 18. The
differentiation ed primarily at the edges of the colonies, sites at which aggregates of
cells formed and inside which human C—peptide, PDXl and insulin were found. More than
half of the es of cells acquired the ability to produce human ide (Figure 18h and
18g), indicative of human insulin synthesis, and this C—peptide synthesis was regulatable by
glucose levels (Figure 1811). The level of human insulin produced was significantly higher in
the cultures in HDM-P as ed with those ing as stem cells under self-
replications conditions. (Figure 19).
The extent of multipotentiality was demonstrated more dramatically if the cells were
placed into distinct 3-D differentiation conditions comprised of the specific HDM (HDM-L,
HDM—C, HDM~P) in combination with embedding the cells in hydrogels containing specific
extracellular matrix components tailored for the adult cell type of interest e 20). The
cells rapidly differentiated (e.g., 7—10 days) to specific adult cell types — yielding cords of
liver cells in HDM-L in combination with hydrogels of hyaluronans containing type IV
collagen and laminin; branching bile ducts, i.e. biliary tree, in HDM-C in combination with
hydrogels of hyaluronans containing type I collagen; or atic neoislets (endocrine
pancreas) if in HDM-P and in hydrogels containing type IV collagen and laminin.
Further evidence for the differentiation under the 3—D culture conditions was found
for Biliary Tree Stem Cells under self-replication conditions (Figure 21, a and b) versus
conditions tailored for hepatocytes e 21, c and d) and then characterized by
transmission electron microscopy. Transmission electron microscopy of Biliary Tree Stem
Cells under self replication conditions (a-b) vs hepatocytes (c-d). Under differentiation
conditions, large and polygonal cells were present, and cell nuclei display one or more
nucleoli. Adjacent cells form well—defined bile canaliculi (arrows). Bile canaliculi are Closed
by junctional complexes (arrowheads). Few microvilli are present in the lumen. The bar on
the figures is equal to 2 am.
Proof that the differentiation conditions resulted in functional adult cells is provided
in Figure 22 containing quantitative RT—PCR data from cultures either under self-replication
conditions ng y stem/progenitors (BP) versus under the 3-D conditions for liver
(B—L), biliary tree/cholangiocytes (B-C), or pancreas (B—P). The top row indicates the
dramatic increase in expression of classic liver --HNF4, AFP, n, tyrosine
ransferase (TAT), errin (TF), and P450-3A4-«in the cultures under conditions
for liver but not under those for the stem/progenitors or for biliary tree or pancreas. By
st, those plated under conditions for pancreas (second row) showed very dramatic
increases in gene expression for PDX-l, ISL—1
, NGN3, insulin, glucagon (GCG) under the
conditions for pancreas (B—P) but not those for rogenitors or liver or biliary tree.
Those plated under conditions for biliary tree demonstrated increases for expression of
GGTl, AE2, CFTR. The cultures of Biliary Tree Stem Cells transferred again under the self—
replication conditions maintained high levels of EpCAM and low levels of all the adult-
specific genes.
This multipotentiality is demonstrated also when the cells are transplanted in vivo
(Figures 23-25). Human Biliary Tree Stem Cells were transplanted into
immunocompromised mice and then tissues evaluated later for presence of engrafted mature
human cells. Even in mice with quiescent livers, that is not subjected to liver injuries, the
cells were able to engraft and mature into cant numbers of cytes (Figure 23) and
giocytes (Figure 24). Moreover, the mice transplanted with the cells driven to a
pancreatic fate were subjected to drugs that made them diabetic, and the transplanted cells
were able to rescue them from the ic condition, and these cells proved to be responsive
to glucose levels in terms of production ofhuman C-peptide (Figure 25).
Although multiple precursors have been identified and shown to differentiate into
mature liver cells, the Biliary Tree Stem Cells identified in the present application, and
t in fetal, neonate, pediatric and adult tissues are the first stem cells and cell
populations identified to date that can be isolated from adult s and proven able to
differentiate to mature pancreatic cell types. These cells are also the first identified that can
be used immediately in clinical programs for diabetes because of their demonstrated ability to
be able to differentiate into pancreatic islet cells, their lack of tumorigenic ial (as exists
for ES cells or cells that are transfected with genes al for differentiation to pancreas),
and lack of immunogenicity.
The Biliary Tree Stem Cells are the natural precursors to pancreas and can
differentiate easily and rapidly (within a few days in cultures) to pancreatic fates merely by
using specific micro-environmental conditions. Moreover, the transition to the clinic is also
facilitated by the fact that the environmental conditions needed are ble in GMP
forms and now are part of extant clinical therapies. Hence, at least one clinical application is
the use of the Biliary Tree Stem Cells described herein for the complete or partial
repopulation, rescue, support, repair, ement or introduction of pancreatic beta-like cells
for treatment of diabetes (Figure 25), or for forms of liver failure, insufficiency, or
degeneration (Figures 23 and 24).
It should be apparent to one of ordinary skill in the art in view of the disclosure herein
that the Biliary Tree Stem Cells have numerous applications in clinical therapy and treatment.
The acquisition of the Biliary Tree Stem Cells can be a vely non~invasive procedure and
relatively harmless to the patient. The ability to propagate these biliary stem cells in vitro
facilitates the y to obtain sufficient cells for clinical programs (e.g., 106-109 cells). The
quantity of stem cells needed for cell therapy programs is readily generated within a few
weeks after the cells are ed, processed and cultured as indicated in Figure 13.
The Biliary Tree Stem Cells provided for therapy can be prepared from a given donor
and then given back to the same person, constituting autologous therapy with no
immunological problems in terms of cell rejection, as cells and ent are preferably
genetically identical. atively, the Biliary Tree Stem Cells or cell populations provided
for therapy can be prepared from a given donor and then given to another person, tuting
allogeneic therapy as the Biliary Tree Stem Cells are non—immunogenic or minimally
immunogenic. Finally, the Biliary Tree Stem Cells according to the invention should be
relatively risk-free in animal experimentation and in cultures with regard to oncogenic
potential. In all in vivo studies to date, there has been no evidence at all of tumorigenic
potential.
In another embodiment of the ion, the Biliary Tree Stem Cells or cell
populations are used for the in vitro tion of target endodermal cells and target
rmal tissue (e,g., pancreas, liver, bile duct). Accordingly, the invention provides and
encompasses methods of producing the “target” cells and tissues from the Biliary Tree Stem
Cells or cell populations, which methods comprise the ion of Biliary Tree Stem Cells,
their incubation under ions that drive their differentiation into the target tissue or cells
of that tissue, and introduction of the cells into a patient in need thereof. ore,
differentiated tissue cells, which are obtained by differentiation of the Biliary Tree Stem Cells
according to the invention, are also subject of the present invention.
As noted above and demonstrated in Figures 14-16, for partial differentiation of the
Biliary Tree Stem Cells towards a specific adult fate, according to the invention, one can use
a defined medium (also called a Hormonally Defined Medium or HDM) containing a specific
mix of nutrients, hormones and growth factors, ideally being serum-free, and tailored to drive
the cells to the adult fate of interest. Representative HDM for cytes, cholangiocytes
versus pancreatic islets are given below. The HDM alone elicits some lineage restriction
towards the desired adult fate but does not elicit full differentiation. Full differentiation
occurs after transplantation in vivo or, if the cells are ex vivo, further requires use of a specific
HDM in combination with a mix of extracellular matrix components, the exact composition
of the mix being unique to the adult cell type desired, and the cells must be established in a
three—dimensional format as described herein. s 17-19.
Particularly preferable forms of application for in vivo differentiation of the Biliary
Tree Stem Cells or cell populations according to the invention are injection, infusion or
implantation by grafting method of the Biliary Tree Stem Cells or cell populations into one
area of the body, in order to allow for the Biliary Tree Stem Cells to differentiate there, by
direct t with cells of the target lineage or infusion of the Biliary Tree Stem Cells or cell
populations to allow for the y Tree Stem Cells or cell populations to reach the target
. For injection or infusion, the Biliary Tree Stem Cells can be administered in a
medium with which they are compatible, such as Kubota’s Medium (or equivalent) or one of
the HDM, or in a graft or implant under conditions comprised of matrix components with
which they are compatible.
Therapeutic applications
For the therapeutic use of the target cells obtainable from the Biliary Tree Stem Cells
or cell populations, according to the invention, a number of concepts are available (see
Science 287: 1442—1446, 2000), which are encompassed by the present invention. Examples
of relevant indications in this connection are: inborn errors of metabolism, liver failure,
cirrhosis of the liver, pancreatic insufficiency, and diabetes.
The inventive y Tree Stem Cells or cell populations can be introduced ly
into or onto the organ to be reconstituted, renewed or repaired. The uction can be
carried out as cell sions, as grafts comprised of the Biliary Tree Stem Cells or cell
populations incorporated into a mix of extracellular matrix ents along with the HDM
or as other types of scaffolds (e.g., microcarriers, polylactides) or as infusions. The scaffolds
are preferably biodegradable, so that they “disappear” from the body, while the newly
introduced cells or cell populations grow together with the existing cells. Cells that may be
reconstituted, rescued, supported, repaired, replaced or introduced in this manner, preferably
by autologous transplant, include islet cells or other pancreas cells, hepatocytes or other liver
cells, and cholangiocytes or other biliary tree cells. Reconstitution, rescue, repair, t,
replacement, or introduction may follow l surgical resection of an organ for repair after
trauma or for supportive use, for example, in the case of lacking or insufficient organ
The Biliary Tree Stem Cells or cell populations according to the invention and target
cells obtained from them can further be bound to implantable materials, in order to increase
biocompatibility. Therefore, also implantable materials, when coated with the y Tree
Stem Cells, are subjects of the invention. The implantable materials can also be artificial
and/or biological carrier or support materials, which n the Biliary Tree Stem Cells or
cell populations and/or target cells derived therefrom. In this regard, the r materials or
support materials can be microcarriers, supports, containers or rs for insertion or
implantation into the human body.
In one such embodiment of the invention, a container with islet cells derived from the
Biliary Tree Stem Cells or cell populations is used for the production of a pharmaceutical
construct for use as an artificial islet cell port chamber to supply insulin in viva. In another
ment of the invention, an infusion or graft of the Biliary Tree Stem Cells or cell
tions is used to reconstitute, rescue, , support, e, or introduce islets or islet
cells in viva. r constructs can be made with hepatocytes or cholangiocytes derived
from the Biliary Tree Stem Cells according to the invention.
The target cells or cell populations obtained from the Biliary Tree Stem Cells cells
according to the invention can in addition be used as cell cultures in bioreactors (e.g., external
to the body), for example in order to carry out detoxification reactions or to produce
substances generated ly in viva by the target cells or tissues. This form of use is
particularly relevant in the case of acute conditions, for example, in the case of acute liver
failure as a bioartificial liver or for severe diabetes as a bioartificial endocrine pancreas.
Finally, the multipotent Biliary Tree Stem Cells or cell populations according to the
invention may be broadly d in transgenic modification and therapy. According to one
embodiment of the invention, the Biliary Tree Stem Cells, or cells or tissue differentiated
therefrom, are transfected with one or more genes. In this way, one or more genes, which are
required to maintain the metabolism of certain organs, such as for e liver or pancreas,
are restored and/or supported or reintroduced. For example, stem cells or hepatocytes can be
transfected with the FAH oylacetoacetate hydrolase) gene. In a FAH—deficient mouse
model, the plenic injection of 1000 FAH-positive donor hepatocytes is sufficient to
completely reconstitute the liver and fully compensate for the lic defect leading to
cirrhosis of the liver. Overturf, K., M. limy, C.-N. Ou, M. Finegold, and M. Grompe.
American Journal of Pathology 151 :1273—1280 (1997). Alternatively, the Biliary Tree Stem
Cells or cell populations can be prepared from a given donor and delivered to r person,
constituting allogeneic therapy, in order to restore, support, or introduce in the recipient one
or more genes required to maintain the metabolism of certain organs, such as, for example,
the liver or pancreas.
The following examples are illustrative of the invention, but the invention is by no
means d to these specific examples. A person of ry skill in the art will find in
these examples but one means to implement the instant invention. Further, while the instant
examples have been presented in the context of non-humans for experimental convenience,
the s and reagents bed herein can be readily translated to human ation(s)
by one of ordinary skill in the art from the teachings disclosed below.
EXAMPLES
EXAMPLE I ~ Cell preparation
Enzymatic dissociation may be carried out in the presence of protease(s), such as
collagenase(s), and/or nuclease(s), such as DNase. Methods of enzymatic dissociation of
liver cells are described and practiced in the art. By way of example, methods for the
isolation and identification of the hepatic progenitors have been described in, for example,
USP No. 6,069,005 and USP Application Nos. 09/487,318; 10/135,700; and 10/387,547, the
disclosures of which are orated herein in their entirety by reference. Indeed, various
ures exist for ation of cell suspensions. It is to be understood, therefore, that the
scope of the present invention is not to be limited to a specific method of procuring whole
tissue or preparing cell suspensions thereof.
EXAMPLE [I —« 3D e conditions
3-dimensional (3—D) gels may be formed by mixing the matrix components, the
hormones, cytokines, growth factors, nutrients and the basal medium into hyaluronans that
are liquid when not cross—linked and become gelled when cross-linked. The details of the
preparation of these are published elsewhere, e.g., W. S. Turner, E. Schmelzer, R.
land et al., J Biomed Mater Res B Appl Biomater 82B (1), 156 (2006); and W. S.
Turner, C. Seagle, J. A. Galanko et al., Stem Cells 26 (6), 1547 (2008), the disclosures of
which are incorporated herein in their entirety. The cultures are typically maintained for 2-4
weeks or longer and then analyzed by histology, gene expression assays such as endpoint and
quantitative , immunofluorescence and protein expression assays such as Western
blots, and metabolomic footprinting.
The major components of the gel complexes are forms of ally-modified
hyaluronans. Carbylan-S (or, CMHA— S) is a carboxymethlated hyaluronan derivative that
has been modified with multiple thiols for inking. All materials are commercially
available from, at least, Glycosan Biosciences (Salt Lake City, Utah).
{0089] Briefly, in one ment, the hyaluronan—matrices are prepared by dissolving
hyaluronan as a dry reagent in Kubota’s Medium to give a 2.0% on (weight/volume).
Laminin (Sigma, St. Louis, Mo) may then be added at a concentration of 1.5 mg/ml and type
IV collagen (Becton Dickenson, Bedford, Ma) at a concentration of 6 mg/ml. Cross-linking
occurs within hours at room temperature and with exposure to oxygen in the air or within
minutes if exposed to a cross~linking reagent, e.g., PEGDA (polyethlylene glycol diacrylate).
So, the solution should be kept chilled at 4 °C and contact with oxygen and/or with PEGDA
d, if cross-linking is not desired.
Upon tion of the experiments, the cells may be recovered by digesting the
hydrogels first with a mix of hyaluronidase (1 mg/ml), DNase (0.5 mg/ml), and dithiothreitol
(4O mgs/ml) prepared in Kubota’s Medium (without transferrin), followed by Liberase (0.5
mg/ml) prepared in Kubota’s Medium without insulin and transferrin. The cells that are
obtained in this manner are le for characterization by flow cytometry, RT-PCR, or
immunohistochemistry.
E III — Evidence of otency
After 7—30 days or longer of culturing Biliary Tree Stem Cells or cell populations
under self-replication conditions (Kubota’s Medium, or lent, in combination with
culture plastic or hyaluronans), monolayer cultures of the remaining cells (116., Biliary Tree
Stem Cells) are transferred to a differentiation medium, n the stem cells undergo rapid
shape changes and changes in gene expression within 48 hours. All the differentiation media
consists of modifications to the medium used for self-replication (e.g., Kubota’s Medium or
equivalent) such that the hormonally defined medium will contain the components in the self—
replication medium plus supplementation with calcium (20.5 mM), copper, bFGF; this is
referred to as “modified medium”. To achieve a specific adult cell type, the following are
required:
Liver: lineage restriction to liver fates (e.g., hepatocytes) may be achieved by
embedding the Biliary Tree Stem Cells into hydrogels ofhyaluronans into which is mixed
type IV collagen and laminin and with the ed medium” further supplemented with
glucagon, ose, triiodothyroxine, epidermal growth factor (EGF) and hepatocyte growth
factor (HGF). In one embodiment, the amount of ients are as follows: MKM
supplemented with 7/,Lg/L glucagon, 2g/L galactose, 10'9 M triiodothyroxine 3, 10 ng/ml EGF
and 20 ng/ml HGF.
Pancreatic tissue: lineage restriction to pancreatic fates (e.g., islets) may be achieved
by embedding the Biliary Tree Stem Cells into a hydrogel of hyaluronans containing type IV
collagen and n and with the “modified medium” further changed to remove
hydrocortisone and to contain B27, ascorbic acid, cyclopamine, Retinoic acid and exendin 4.
In one embodiment, the amount of ients are as follows: MKM modified to remove
hydrocortisone and n 2% B27, 0.1 mM ascorbic acid, 0.25 uM cyclopamine, 0.5uM
Retinoic acid and 50ng/ml exendin 4.
Biliary holangiocytes: similarly, the Biliary Tree Stem Cells can be lineage
restricted to biliary fates (e.g., cholangiocytes) by embedding the stem cells into hyaluronans
mixed with type I collagen and in the “modified medium” r supplemented with vascular
endothelial cell growth factor (VEGF) 165 and HGF. In one embodiment, the amount of
ingredients are as follows: MKM r supplemented with 20 ng/ml vascular elial
cell growth factor (VEGF) 165 and 10 ng/ml HGF.
EXAMPLE IV — Transplantation
Transplantation of cells from solid organs via grafting protocols are preferable over
injection or infusion for many applications, although either mode of delivery is feasible. It
has been found that the hydrogel cultures described hereinabove provide good conditions for
grafting. The cells can be suspended in the un—crosslinked hyaluronans, mixed with other
matrix components in medium sing basal medium plus hormones, growth factors and
other soluble signals tailored for expansion and/or differentiation.
The cell populations used for the transplantation preferably se Biliary Tree
Stem Cells or cell populations that are transplanted along with (or without) their native
mesenchymal partners (e.g., angioblasts, stellate cells), derived from the target tissue (or
other source) for the transplantation, and at ratios paralleling those found in viva. Without
being held to or bound by theory, it is believed that this combination of the stem cells and the
partner mesenchymal cells provides the appropriate microenvironment for full maturation of
tissues that are vascularized and able to function logically.
In one embodiment, for pancreatic grafts, implants, or injections, the cellular
components of the grafts may consist of the Biliary Tree Stem Cells or cell populations co-
seeded into the graft with human fetal or neonatal tissue-derived angioblasts (VEGFR:
CDl l7+ cells) and stellate cells + cells) at an estimated ratio of those cell populations
found in vivo in the tissue. The stem cell populations may be obtained from ing cells
in culture as described herein. The angioblasts and stellate cells may be immunoselected
with magnetically ted cell sorting (MACS) system or flow cytometric sorts from freshly
ed cell suspensions ofhuman fetal or neonatal pancreas tissue.
All of the biliary tree stem cell populations can be immunoselected for cells positive
for a cell surface marker common to stem/progenitors (6g, CD133, CD44H, EpCAM,
NCAM). In one embodiment, the cells are ted at 4 °C for 20 minutes at a
concentration of 50 Ml for 50 x 106 total cells in 500 Ml phosphate buffered saline (PBS)
containing 0.5% bovine serum albumin and 2 mM EDTA with FITC—conjugated primary
antibodies. The cells so labeled are reacted with magnetic beads using anti~FITC antibodies
and then selected by Midi— or MiniMACS columns and separation units. All incubation and
selection steps should be performed on ice with addition of 10% ACCUTASE ative
Cell Technologies, San Diego, CA) to t aggregation of cells. Alternatively, the cells
can be labeled with a fluoroprobe-labeled antibody and the cells immunoselected using flow
cytometer.
EXAMPLE V — Media
All media were sterile—filtered (0.22—um filter) and kept in the dark at 4°C before use.
Kubota’s medium (KM) consists of any basal medium (e.g., RPMI 1640) with no copper, low
calcium (<0.5 mM), 10'9 M selenium, 4.5 mM nicotinamide, 0.1 nM zinc sulfate, 10‘8 M
hydrocortisone, 5 ug/ml errin/Fe, 5 [1ng insulin, a mixture of free fatty acids that are
added bound to serum albumin (0.1%) and, optionally, 10 ug/ml high density lipoprotein.
EXAMPLE VI — Differentiation conditions
Three dimensional es were established With hydro gels containing
hyaluronans, other matrix molecules, hormones, growth factors, cytokines, all prepared in a
m. All of the els were made using modified Kubota’s Medium (or equivalent)
that was supplemented with calcium to achieve 0.6 mM concentration, 10"12 M copper, and
um ofbasic fibroblast growth factor (bFGF) (referred to as modified KM or MKM):
Liver cells: MKM-L with 7rig/L glucagon, 2g/L galactose, 10'9 M tri-
yroxine 3, 10 ng/ml epidermal growth factor (EGF) and 20 ng/ml hepatocyte growth
factor (HGF). The matrix scaffolds consisted of 60% type IV collagen and laminin and 40%
hyaluronans.
Biliary holangiocytes: MKM—C supplemented with 20 ng/ml vascular
endothelial cell growth factor (VEGF) 165 and 10 ng/ml HGF. The matrix scaffolds
consisted of 60% type I collagen and 40% hyaluronans.
Pancreas islets: MKM-P (without hydrocortisone) r supplemented with
2% B27, 0.1 mM ascorbic acid, 0.25 uM cyclopamine, 0.5uM RA and 50ng/ml exendin~4.
The matrix lds consisted of 60% type IV collagen and laminin and 40% hyaluronans.
EXAMPLE VII — Cell isolation and phenogyning
Human biliary tissues were ed from livers and pancreases obtained for
and then rejected for transplantation into a patient. Cell suspensions of human biliary s
were processed using RPMI 1640 supplemented with 0.1% bovine serum albumin, 1 nM
um and antibiotics. Enzymatic processing buffer contained 300U/ml type IV
collagenase and 0.3 mg/ml ibonuclease at 32 0C with frequent agitation for 15—20 min.
Enriched sions were pressed through a 75 gauge mesh and spun at 1200 RPM for 5
min before resuspension. Estimated cell viability by trypan blue exclusion was routinely
higher than 95%.
Approximately 3x105 cells were plated on a 10 cm tissue culture dish and in
serum-free Kubota’s Medium, which was replaced every 3 days. Colonies formed within 5-7
days and were observed for up to 3 months. Colonies were picked by hand at varying times
using an ed microscope.
Multipotent Biliary Tree Stem Cells were also isolated by immunoselection
from freshly prepared cell suspensions based on positive expression of one or more cell
e s common to stem/progenitors (CD133, CD44H, NCAM, EpCAM-— CD326)
using magnetic bead immunoselection technologies with the Miltenyi Biotech MACS system
(Bergisch Gladbach, Germany) following the manufacturer’s instructions. Briefly,
iated cells were incubated with EpCAM antibody bound to magnetic microbeads for 30
min at 4 0C, and were separated using magnetic column separation system from Miltenyi
ing the manufacturer’s recommended procedures. Medium was ed daily and
ted medium was stored at —20 °C for further is.
For the fluorescent staining, cells were fixed with 4% paraformaldehyde
(PFA) for 20 min at room temperature, rinsed with HBSS, blocked with 10% goat serum in
HBSS for 2 h, and rinsed. Fixed cells were incubated with primary antibodies at 4 0C over
night, washed, incubated for 1h with labeled isotype—specific secondary antibodies, washed,
counterstained with 4’,6-diamidino—2-phenylindole (DAPI) for visualization of cell nuclei.
] For immunohistochemistry, tissues were fixed in 4% paraformaldehyde (PFA)
overnight, stored in 70% ethanol, and subsequently embedded in paraffin and cut into 5 um
sections. Sections were deparaffinized, and the antigens were retrieved. Endogenous
peroxidases were blocked by incubation for 30 min in 0.3% H202 solution. After blocking
with 10% horse serum, primary antibody was applied at 4 0C over night; secondary antibody
and ABC staining were performed using the RTU Vectastain kit (Vector Laboratories,
Burlingame, CA). Vector Nova RED was used as substrate. Sections were dehydrated, fixed
and embedded in Eukitt Mounting Media (Electron Microscopy Sciences, Hatfield, PA), and
were analyzed using an inverted microscope.
For quantitative reverse-transcription polymerase chain reaction R)
analysis, biliary tree tissue or cells from culture were lysed and total RNA extracted using
RNeasy Plus Mini Kit (Qiagen GmbH, Valencia CA) as per the manufacturer’s instructions.
Reverse transcription was carried out with the SuperScript First—Strand Synthesis System for
RT-PCR (lnvitrogen, ad, CA). HotStarTaq Master Mix Kit (Qiagen) was used for
PCR.
] Cells were analyzed and sorted by a FACStar Plus cell sorter (BD
ences) ed with dual Coherent 1—90 lasers. scence—conjugated antibodies
were excited at 488 nm, and their fluorescence emission was detected by standard filters.
While the invention has been described in connection with specific
embodiments thereof, it will be understood that it is capable of further modifications and this
ation is intended to cover any variations, uses, or alterations of the invention ing
such as variations in the precise concentrations of matrix components or growth s or
hormones to elicit precise responses from the cells. In general, the principles of the
invention, and including such departures from the t disclosure as come within known
or customary practice within the art to which the invention pertains, may be applied to the
essential features hereinbefore set forth and as follows in the scope of the appended claims.
] Abbreviations: AE2, anion exchanger 2; AFP, a—fetoprotein; ALB, albumin;
ASMA, alpha-smooth muscle actin; ASBT, Apical sodium—dependent bile acid transporter;
bFGF, basic fibroblast growth factor; CD, common determinant; CD133, prominin; CD146,
Mel-CAM; CD31, PECAM; CD44H, hyaluronan receptor; CD45, common leucocyte
antigen; CFTR, cystic fibrosis transmembrane conductance regulator; CK, cytokeratin;
CXCR4, CXC-chemokine receptor 4; CYP450, Cytochrome P450; EGF, mal growth
factor; EpCAM, epithelial cell adhesion molecule; FOXaZ, forkhead box a2; GGT, gamma
glutamyl transpeptidase; HDM, hormonally defined medium, one tailored for a c cell
type; HDM—L, hormonally defined medium for liver; HDM-C, hormonally defined medium
for cholangiocytes (biliary tree); HDM-P, hormonally defined medium for pancreas; HGF,
hepatocyte growth factor; HNF, hepatocyte nuclear factor; KM, Kubota’s Medium, a serum-
free medium designed for stem/progenitors; NCAM, neural cell adhesion molecule; NGN3,
enin 3; PDXl, Pancreatic and duodenal homeobox l; PROXl, Prospero homeobox
protein 1; SALL4, Sal-like protein 4; SOX, Sry-related HMG box; SR, sccrctin receptor;
VEGF, vascular elial growth factor.
Claims (3)
1. An isolated mammalian multipotent stem/progenitor cell capable of differentiating into atic, liver and biliary cells, wherein the cell is obtained in vitro from extrahepatic biliary tree tissue of a mammal and wherein the cell exhibits at least one of the ing: (i) nuclear expression of telomerase protein; (ii) low to moderate levels of expression of otency genes; (iii) expression of endodermal stem/progenitor surface markers; wherein the cell ts expression of endodermal transcription factors; wherein the cell lacks expression or expression of low and variable levels of lineage markers of mature liver, mature bile duct, or mature endocrine pancreas, such as hepatocytes, cholangiocytes, or islet cells; and wherein the cell lacks expression of s for mesenchymal cells, endothelial cells or hemopoietic cells.
2. The ed mammalian otent stem/progenitor cell of Claim 1, in which: the endodermal surface markers include one of the following: CD326/Epithelial cell adhesion molecule ), CD56/Neuronal cell adhesion molecule (NCAM), CD 133 (prominin), CXCR4, or combinations thereof; or the endodermal ription factors include one of the following: SOX17, SOX 9, FOXA2, HES l , HNF6, PROXl, HNF3B (hepatocyte nuclear factor-3B), PDX 1, NGN3, or combinations thereof; or the lineage markers of mature liver, such as hepatocytes, include one of the following P450s such as A4; lineage markers for mature bile duct such as cholangiocytes, include one of the following: secretin receptor, aquaporins, or combinations thereof; and the lineage markers for mature pancreas such as islet cells include one of the following: high levels of insulin, glucagon, somatostatin, amylase or combinations thereof; or the marker for mesenchymal cells is desmin, the marker for endothelial cells is VEGF receptor, and the marker for hemopoietic cells is CD45.
3. A composition comprising: a population of cells comprising the mammalian multipotent stem/progenitor cell according to Claim 1 or 2; or a population of mammalian cells enriched for multipotent rogenitor cells according to Claim 1 or 2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25684609P | 2009-10-30 | 2009-10-30 | |
US61/256,846 | 2009-10-30 | ||
NZ709124A NZ709124A (en) | 2009-10-30 | 2010-10-28 | Multipotent stem cells from the extrahepatic biliary tree and methods of isolating same |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ724435A NZ724435A (en) | 2021-02-26 |
NZ724435B2 true NZ724435B2 (en) | 2021-05-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016210783B2 (en) | Multipotent stem cells from the extrahepatic billary tree and methods of isolating same | |
CN110317775B (en) | Culture medium for hepatocyte culture and liver organoid preparation | |
US9127254B2 (en) | Scaffolding for tissue regeneration or repair | |
US20030235563A1 (en) | Placental derived stem cells and uses thereof | |
AU2010313386B2 (en) | Multipotent stem cells from the extrahepatic billary tree and methods of isolating same | |
NZ724435B2 (en) | Multipotent stem cells from the extrahepatic biliary tree and methods of isolating same | |
RU2663118C1 (en) | Cell product of insulin-producing mammalian cells and use thereof for diabetes mellitus therapy |